期刊文献+

银杏叶提取物对白介素-1β损伤关节软骨细胞自由基体系的影响 被引量:1

原文传递
导出
摘要 目的:观察银杏叶提取物对白介素-1β损伤的关节软骨细胞的作用及对细胞内自由基的影响。方法:在无菌环境下消化得到3月龄雌性新西兰白兔膝关节软骨细胞,实验用细胞为第2代软骨细胞。软骨细胞与IL-1β(5μg/L)、IL-1β(5μg/L)+地塞米松(10-7、10-6、10-5mmol/L)、IL-1β(5μg/L)+银杏叶提取物EGb761(40、80、160mg/L)共同孵育,分别在72h后MTT法检测软骨细胞的增殖受到的影响,24h后测定受损伤软骨细胞培养液中的MDA、SOD、NO。结果:MTT法显示IL-1β对软骨细胞的增殖有明显的抑制作用;地塞米松同EGb761均可对抗IL-1β的效应。地塞米松和EGb均能显著减少MDA、NO的生成(P<0.01),增多SOD的生成。EGb761的这种效应有剂量依赖性。结论:银杏叶提取物EGb761通过清除软骨细胞内的自由基对IL-1β损伤的膝关节软骨细胞的具备很好的保护效应。
作者 赵东杰
出处 《中华中医药杂志》 CAS CSCD 北大核心 2009年第S1期81-83,共3页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 杭州市卫生局(No.2006B038)
  • 相关文献

参考文献9

  • 1高春阳,赵育松.一氧化氮在骨性关节炎发病机制中的作用[J].国外医学(免疫学分册),2001,24(3):159-162. 被引量:7
  • 2Maitra I,Marcocci L,Droy-Lefaix MT,et al.Peroxyl radical scavenging activaty of Ginkgo biloba extract EGB761. Biochemical Pharmacology . 1995
  • 3DeFeudis FV,Drieu K.Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Current Drug Targets . 2000
  • 4Farrel AJ,Blade DR,Ralmer RM,et al.Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Annals of the Rheumatic Diseases . 1992
  • 5Hashimoto S,Takahashi K,Amiel D,et al.Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis and Rheumatism . 1998
  • 6Ushmorov A,Ratter F,Lehmann V,et al.Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. Blood . 1999
  • 7Alderton WK,Cooper CE,Knowles RG.Nitric oxide synthases: structure, function and inhibition. Biochemical Journal . 2001
  • 8Dubey AK,Shankar PR,Upadhyaya D,et al.Ginkgo biloba--an appraisal. Kathmandu Univ Med J (KUMJ) . 2004
  • 9Wang Bochu,Zhu Liancai,Chen Qi.Primary study on the application of Serum Pharmacology in Chinese traditional medicine. Colloids and Surfaces . 2005

共引文献6

同被引文献13

  • 1刘国艳,瞿全新,糜若然,齐静.RNA干扰技术抑制切除修复交叉互补基因1对卵巢上皮性癌细胞顺铂敏感性的影响[J].中华妇产科杂志,2006,41(5):339-342. 被引量:20
  • 2Ledermann J A.Primary chemotherapy:the future for themanagement of advanced ovarian cancer?.Int J GynecolCancer,2010,20 (Suppl2):S17-S19.
  • 3Gossage L,Madhusudan S.Current status of excision repaircross complementing-group 1(ERCC1)in cancer.Cancer TreatRev,2007,33(6):565-577.
  • 4Fareed K R,Al-Attar A,Soomro I N,et al.Tumour regression andERCC1 nuclear protein expression predict clinical outcome inpatients with gastro-oesophageal cancer treated with neoadjuvantchemotherapy.BrJCancer,2010,102(11):1600-1607.
  • 5Ye B,Aponte M,Dai Y,et al.Ginkgo biloba and ovarian cancerprevention:epidemiological and biological evidence.CancerLett,2007,251(1):43-52.
  • 6Jiang W,Qiu W,Wang Y,et al.Ginkgo may prevent genetic-associated ovarian cancer risk:multiple biomarkers and anticancerpathways induced by ginkgolide B in BRCA1-mutant ovarianepithelialcells.EurJCancerPrev,2011,20(6):508-517.
  • 7Agarwal R,Kaye S B.Ovarian cancer:strategies for overcomingresistancetochemotherapy.NatRevCancer,2003,3(7):502-516.
  • 8McdanielLD,SchultzRA.XPF/ERCC4andERCC1:theirproductsandbiologicalroles.AdvExpMedBiol,2008,637:65-82.
  • 9Krivak T C,Darcy K M,Tian C,et al.Relationship between ERCC1polymorphisms,disease progression,and survival in the gynecologiconcology group phaseⅢtrial of intraperitoneal versus intravenouscisplatin and paclitaxel for stageⅢepithelial ovarian cancer.J ClinOncol,2008,26(21):3598-3606.
  • 10Aponte M,Jiang W,Lakkis M,et al.Activation of platelet-activatingfactor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillininovariancancer.CancerRes,2008,68(14):5839-5848.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部